Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2746 to 2760 of 9128 results

  1. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy ID6711

    In development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625

    In development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 3 July 2026.

    In consultation

  5. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 13 August 2026.

    Technology appraisal guidance
    In consultation

  6. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development

  7. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy ID6711: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 13 August 2026.

    Technology appraisal guidance
    In consultation

  8. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 March 2027

    NICE guideline
    In development

  9. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over (review of HST31) [ID6598]: draft guidance

    We are listening to your views on this Highly specialised technology. Comments close 7 August 2026.

    Highly specialised technologies guidance
    In consultation

  10. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  14 October 2026

    Highly specialised technologies guidance
    In development

  11. Early and locally advanced breast cancer: diagnosis and management (update)

    Awaiting development Reference number: GID-NG10557 Expected publication date: TBC

    NICE guideline
    Awaiting development

  12. Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  13. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  14. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date:  27 January 2027

    Technology appraisal guidance
    In development

  15. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 1 or more treatment lines in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development